指南与共识泌尿男性生殖肿瘤

2025年晚期泌尿系统肿瘤共识会议:肾细胞癌与尿路癌管理专家共识

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.
指南 / 共识 · CA Cancer J Clin · 2026-01-01

2025年晚期泌尿系统肿瘤共识会议采用改良Delphi流程,由51位多学科专家对肾细胞癌和尿路癌管理问题投票,共识定义为≥75%一致、强共识为>90%。会议就辅助帕博利珠单抗用于高危肾细胞癌、膀胱切除术前新辅助治疗、恩沃利单抗联合帕博利珠单抗一线治疗转移性尿路癌等达成强共识,但在多个关键领域缺乏共识。

要点

  • 高危肾细胞癌术后辅助帕博利珠单抗获强共识。
  • 局限尿路癌膀胱切除术前新辅助治疗获强共识。
  • 转移性尿路癌一线恩沃利单抗联合帕博利珠单抗获强共识。

核心结论

  • 会议就肾细胞癌和尿路癌多个临床场景达成专家共识,同时指出多个领域缺乏共识并需前瞻性研究。

研究设计与样本

  • 2025年晚期泌尿系统肿瘤共识会议采用改良Delphi流程,由51位多学科专家参与,会前会后投票,分析会后应答,共识定义为≥75%一致、强共识为>90%。

主要发现

  • 高危肾细胞癌(pT2分级4、pT3-pT4任何分级、pTXN1或完全切除的转移性疾病)辅助帕博利珠单抗获强共识。
  • 局限尿路癌膀胱切除术前新辅助治疗获强共识。
  • 转移性尿路癌一线恩沃利单抗联合帕博利珠单抗获强共识。
  • 生物标志物阴性尿路癌进展后铂类化疗获强共识。
  • 肾细胞癌一线免疫检查点抑制剂联合血管内皮生长因子受体酪氨酸激酶抑制剂或双免疫检查点抑制剂进展后,单药血管内皮生长因子受体酪氨酸激酶抑制剂治疗获共识。

关键数值与推荐

  • 共识阈值:≥75%一致为共识,>90%为强共识。

临床怎么用

  • 会议结果为肾细胞癌和尿路癌复杂临床场景提供循证指导,并识别关键研究优先级。

局限性

  • 多个关键领域缺乏共识,凸显需改进患者选择并开展前瞻性研究以优化联合与序贯治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The therapeutic landscape for renal cell carcinoma (RCC) and urinary tract cancer (UTC) has transformed dramatically, creating complexity in treatment selection and sequencing. The 2025 Advanced Urologic Cancer Consensus Conference was convened to establish evidence-based expert consensus recommendations for optimal management. A multidisciplinary panel of 51 experts participated in a modified Delphi process addressing questions developed through iterative consensus-building covering RCC and UTC management. Voting occurred before and after the conference, and analyses focused on postmeeting responses. Consensus was defined as ≥75% agreement, with strong consensus as >90%. Strong consensus was found on the use of adjuvant pembrolizumab for higher risk RCC (pathologic T2 [pT2], grade 4; pT3-pT4, any grade; pTXN1; or fully resected metastatic disease) and on neoadjuvant therapy before cystectomy for localized UTC. There was strong consensus on the use of enfortumab vedotin plus pembrolizumab as frontline therapy for metastatic UTC and the use of platinum-based chemotherapy postprogression in biomarker-negative UTC. For RCC, there was consensus on the role of single-agent vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy after progression on frontline immune checkpoint inhibitor/vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy or dual immune checkpoint inhibitor therapy. However, there was a lack of consensus on other critical areas in the management of RCC and UTC. The 2025 Advanced Urologic Cancer Consensus Conference provides evidence-informed guidance for complex clinical scenarios while identifying critical research priorities. The group recognizes that the lack of consensus across multiple areas highlights the need for improved patient selection and prospective studies enabling optimal combination and sequencing approaches. This iterative annual process will address evolving treatment paradigms to optimize outcomes.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers. CA Cancer J Clin. 2026. PMID: 41389316. doi:10.3322/caac.70052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。